Abstract
The institutional review board (IRB) is a federally mandated group instituted by the U.S. government to protect the rights and welfare of human subjects engaged in clinical research. Research involving human subjects, whether living individuals, data, or specimens, requires IRB approval and oversight prior to implementation. Investigators must conduct research in accordance with federal regulations, state and local laws, relevant policies and procedures, and ethical principles. IRBs provide oversight by reviewing and monitoring research to ensure research is conducted in a scientific, safe, and ethical manner and in compliance with research regulations. This chapter describes the role and purpose of the IRB in protecting the rights and welfare of human subjects in research in the United States, reviews federal regulatory standards relevant to IRB oversight, discusses research involving special populations, and comments on the non-research functions of the IRB.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Biros, M. (2018). Capacity, vulnerability, and informed consent for research. The Journal of Law, Medicine & Ethics, 46(1), 72–78.
Breault, J. L. (2006). Protecting human research subjects: The past defines the future. The Ochsner Journal, 6(1), 15–20.
Chappell, P. B., Mahableshwarkar, A. R., Alphs, L. D., Bangs, M. E., Butler, A., DuBrava, S. J., & Stewart, M. (2014). Prospective assessment of suicidal ideation and behavior: An internet survey of pharmaceutical sponsor practices. Innovations in Clinical Neuroscience, 11(9–10), 14–22.
Department of Health Education and Welfare. (1979). The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. Department of Health Education and Welfare.
Gamble, V. N. (1997). Under the shadow of Tuskegee: African Americans and health care. American Journal of Public Health, 87(11), 1773–1778.
Gordon, B. G. (2020). Vulnerability in research: Basic ethical concepts and general approach to review. The Ochsner Journal, 20(1), 34–38.
Jonsen, A. R. (1978). Research involving children: Recommendations of the national commission for the protection of human subjects of biomedical and behavioral research. Pediatrics, 62(2), 131–136.
Lapid, M. I., Clarke, B. L., & Wright, R. S. (2019). Institutional review boards: What clinician researchers need to know. Mayo Clinic Proceedings, 94(3), 515–525.
Mastroianni, A. C., Henry, L. M., Robinson, D., Bailey, T., Faden, R. R., Little, M. O., & Lyerly, A. D. (2017). Research with pregnant women: New insights on legal decision-making. The Hastings Center Report, 47(3), 38–45.
National Archives and Records Administration’s Office of the Federal Register, & Government Publishing Office. (2017). PART 46 – Protection of human subjects. Electronic Code of Federal Regulations. Retrieved from https://www.ecfr.gov/on/2018-07-19/title-45/subtitle-A/subchapter-A/part-46#sp45.1.46.a
National Institutes of Health (NIH). (2021). Single IRB for multi-site or cooperative research. Retrieved from https://grants.nih.gov/policy/humansubjects/single-irb-policy-multi-site-research.htm
Office for Human Research Protections. (2007). Reviewing and reporting unanticipated problems involving risks to subjects or others and adverse events: OHRP guidance (2007). Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/guidance/reviewing-unanticipated-problems/index.html#Q1
Office for Human Research Protections. (2011). Guidance on reporting incidents to OHRP (2011). Retrieved from https://www.hhs.gov/ohrp/compliance-and-reporting/guidance-on-reporting-incident/index.html
Office for Human Research Protections. (2016a). Federal policy for the protection of human subjects (‘Common Rule’). Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule/index.html
Office for Human Research Protections. (2016b). Institutional review board (IRB) written procedures: Guidance for institutions and IRBs. Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/requests-for-comments/guidance-for-institutions-and-irbs/index.html
Office for Human Research Protections. (2017a). Federal wide assurance (FWA) for the protection of human subjects. Retrieved from https://www.hhs.gov/ohrp/register-irbs-and-obtain-fwas/fwas/fwa-protection-of-human-subjecct/index.html
Office for Human Research Protections. (2017b). Revised common rule. Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/regulations/finalized-revisions-common-rule/index.html
Office for Human Research Protections. (2021a). Children: Information on special protections for children as research subjects. Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/guidance/special-protections-for-children/index.html
Office for Human Research Protections. (2021b). Exempt research determination FAQs. Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/guidance/faq/exempt-research-determination/index.html
Office for Human Research Protections. (2021c). Exemptions (2018 Requirements). Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/common-rule-subpart-a-46104/index.html
Office for Human Research Protections. (2021d). Expedited review procedures guidance (2003). Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/guidance/guidance-on-expedited-review-procedures/index.html
Office for Human Research Protections. (2021e). Quality improvement activities FAQs. Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/guidance/faq/quality-improvement-activities/index.html
Office for Human Research Protections. (2021f). Subpart C — additional protections pertaining to biomedical and behavioral research involving prisoners as subjects. Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/common-rule-subpart-c/index.html
Office for Human Research Protections. (2021g). Subpart D – Additional protections for children involved as subjects in research. Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/common-rule-subpart-d/index.html
One Hundred Fifteenth Congress of the United States of America. (2018). Right to try act. Retrieved from https://www.congress.gov/115/bills/s204/BILLS-115s204enr.pdf
Pennsylvania General Assembly. (2006). 2006 act 169. Retrieved from https://www.legis.state.pa.us/cfdocs/Legis/LI/uconsCheck.cfm?txtType=HTM&yr=2006&sessInd=0&smthLwInd=0&act=169
Ramnath, K., Cheave, S., Buchanan, L., Borror, K., & Banks-Shields, M. (2016). Incident reports and corrective actions received by OHRP. IRB, 38(6), 10–15.
Rose, C. D. (2017). Ethical conduct of research in children: Pediatricians and their IRB (part 2 of 2). Pediatrics, 139(6), e20163650.
Snyder, J., Bateman-House, A., & Turner, L. (2020). Is right to try being tried? Using crowdfunding data to better understand usage of nontrial pre-approval access pathways. Regenerative Medicine, 15(8), 1979–1985.
Stark, L., & Greene, J. A. (2016). Clinical trials, healthy controls, and the birth of the IRB. The New England Journal of Medicine, 375(11), 1013–1015.
Stewart, M., Butler, A., Alphs, L., Chappell, P. B., Feltner, D. E., Lenderking, W. R., & Dubrava, S. (2013). Study site experiences and attitudes toward prospective assessments of suicidal ideation and behavior in clinical trials: Results of an internet-based survey. Innov. Clinical Neuroscience, 10(5–6 Suppl A), 20s–28s.
The Columbia Lighthouse Project. (2021). The columbia protocol (C-SSRS). Retrieved from https://cssrs.columbia.edu/
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2020). ICH guidelines. Retrieved from https://www.ich.org/page/ich-guidelines
U.S. Department of Health & Human Services. (2021). HHS historical highlights. Retrieved from https://www.hhs.gov/about/historical-highlights/index.html
U.S. Department of Health and Human Services, Food and Drug Administration, Office of Good Clinical Practice, Center for Drug Evaluation and Research (CDER), & Center fo Biologics Evaluation and Research (CBER). (2010). Information sheet guidance for sponsors, clinical investigators, and IRBs. Retrieved from https://www.fda.gov/media/78830/download
U.S. Food and Drug Administration. (2006). Human subject protection-information for institutional review boards, clinical investigators, and sponsors; rescission, reissuance, and development of food and drug administration guidance documents; availability. Retrieved from https://www.federalregister.gov/documents/2006/02/03/E6-1476/human-subject-protection-information-for-institutional-review-boards-clinical-investigators-and. Retrieved 10/31/2021, from Federal Register https://www.federalregister.gov/documents/2006/02/03/E6-1476/human-subject-protection-information-for-institutional-review-boards-clinical-investigators-and
U.S. Food & Drug Administration. (1996). Institutional review boards frequently asked questions. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-boards-frequently-asked-questions
U.S. Food & Drug Administration. (2015). IND Application procedures: Exemptions from IND requirements. Retrieved from https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-procedures-exemptions-ind-requirements
U.S. Food & Drug Administration. (2017). Humanitarian use device (HUD) designation program. Retrieved from https://www.fda.gov/industry/develo**-products-rare-diseases-conditions/humanitarian-use-device-hud-designation-program
U.S. Food & Drug Administration. (2018a). Medical device overview. Retrieved from https://www.fda.gov/industry/regulated-products/medical-device-overview
U.S. Food & Drug Administration. (2018b). FDA fact sheet: Right to try. Retrieved from https://www.fda.gov/media/133864/download
U.S. Food & Drug Administration. (2018c). Guidance for industry: Suicidal ideation and behavior: Prospective assessment of occurrence in clinical trials. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-suicidal-ideation-and-behavior-prospective-assessment-occurrence-clinical-trials
U.S. Food & Drug Administration. (2018d). Part II: 1938, food, drug, cosmetic act. Retrieved from https://www.fda.gov/about-fda/changes-science-law-and-regulatory-authorities/part-ii-1938-food-drug-cosmetic-act
U.S. Food & Drug Administration. (2019a). Informed consent: Guidance for IRBs, clinical investigators, and sponsors. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent#about
U.S. Food & Drug Administration. (2019b). Institutional review boards (IRBs) and protection of human subjects in clinical trials. Retrieved from https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/institutional-review-boards-irbs-and-protection-human-subjects-clinical-trials
U.S. Food & Drug Administration. (2020a). CFR – Code of federal regulations title 21. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50&showFR=1&subpartNode=21:1.0.1.1.20.4
U.S. Food & Drug Administration. (2020b). CFR – Code of federal regulations title 21. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=56.107
U.S. Food & Drug Administration. (2020c). Right to try. Retrieved from https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try
U.S. Food & Drug Administration. (2021). Investigational new drug (IND) application. Retrieved from https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
World Medical Association. (2018). WMA declaration of Helsinki – ETHICAL principles for medical research involving human subjects. Retrieved from https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
Acknowledgment
The authors gratefully acknowledge the assistance of Ms. Angie Lam with manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lapid, M.I., Ouellette, Y., Drake, M.T., Clarke, B.L. (2023). Institutional Review Board (IRB): US Perspectives. In: Valdés, E., Lecaros, J.A. (eds) Handbook of Bioethical Decisions. Volume II. Collaborative Bioethics, vol 3. Springer, Cham. https://doi.org/10.1007/978-3-031-29455-6_15
Download citation
DOI: https://doi.org/10.1007/978-3-031-29455-6_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-29454-9
Online ISBN: 978-3-031-29455-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)